Skip to main content
. 2022 Jul 22;12:948293. doi: 10.3389/fonc.2022.948293

Table 1.

Baseline patient characteristics for current report and previously reported cases.

Case Age Sex Child-Pugh class, score ALBIgrade, score Tumor stage TNM, BCLC History of MTAtreatment History of hepaticresection Etiology Platelet(×105/μl) Splenomegaly, splenic index Reason for discontinuation of AB treatment
1 70 M A, 6 2, -1.81 IVB, C HCV (SVR) 4.9 +, 985 AE
2 78 M A, 6 2, -2.01 III, B + + NASH 9.4 -, 391 AE
3 61 M B, 7 2, -1.50 IVB, C + + HCV 12.0 +, 793 AE
4 55 M A, 5 2, -2.57 IVB, C NASH 7.7 +, 1688 AE
5 69 M A, 5 2, -2.45 III, B + Alcohol 7.6 +, 2099 AE
6 37 M A, 6 2, -1.67 IVB, C + + NASH 7.7 +, 553 PD
7 72 M A, 6 2, -1.94 III, B Alcohol 6.2 +, 1136
Median (range) 69 (37–78) -1.94 (-1.67–2.57) 7.7 (4.9–12.0) 985 (391–2099)
13, Case 1 60s M A, 5 2, -2.78 IVB, C + + HCV (SVR) 11.1 Spleen volume, 193 cm3 NA
13, Case 2 60s M A, 6 2, -2.16 III, B + HCV (SVR) 12.6 Spleen volume, 262 cm3 NA

ALBI, albumin-bilirubin index; BCLC, Barcelona Clinic Liver Cancer; MTA, molecular targeted agent; AB, atezolizumab plus bevacizumab; HCV, hepatitis C virus; SVR, sustained virological response; AE, adverse event; NASH, non-alcoholic steatohepatitis; PD, progressive disease; Ref., reference; NA, not available.